Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With or Without Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
NCT05721755Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jun 2023
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Overall Survival up to 3 years. Started Jun 2023; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05721755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721755.